Report
Oussema Denguir

Innate Pharma : Un nouveau deal transformant avec Astrazeneca. Achat vs Neutre

>Asset swap avec AZN : Innate devient une société commerciale ! - Innate Pharma annonce ce matin un nouveau deal transformant avec son partenaire Astrazeneca : 1/ d’une part IPH réalise l’acquisition des droits commerciaux aux Etats-Unis et en Europe de Lumoxiti (moxetumomab pasudotox-tdfk), un traitement contre la leucémie à tricholeucocytes – une maladie rare, environ 1 000 cas par an aux Etats-Unis - développé par AstraZeneca et approuvé par la FDA le 13 septembre ...
Underlying
Innate Pharma SA Class A

Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Oussema Denguir

ResearchPool Subscriptions

Get the most out of your insights

Get in touch